Business Description
Agios Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00847X1046
Share Class Description:
AGIO: Ordinary SharesCompare
Compare
Traded in other countries / regions
AGIO.USA8AP.Germany0HB0.UKAGIO.Mexico IPO Date
2013-07-24Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.79 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -0.19 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 6.44 | |||||
| Beneish M-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -13.5 | |||||
| 3-Year EPS without NRI Growth Rate | -9.9 | |||||
| 3-Year FCF Growth Rate | -8.6 | |||||
| 3-Year Book Growth Rate | 36 | |||||
| Future 3-5Y Total Revenue Growth Rate | 94.57 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.31 | |||||
| 9-Day RSI | 52.08 | |||||
| 14-Day RSI | 51.92 | |||||
| 6-1 Month Momentum % | 29.5 | |||||
| 12-1 Month Momentum % | 36.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.27 | |||||
| Quick Ratio | 11.99 | |||||
| Cash Ratio | 11.43 | |||||
| Days Inventory | 1821.5 | |||||
| Days Sales Outstanding | 27.82 | |||||
| Days Payable | 1569.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 6.9 | |||||
| Shareholder Yield % | 0.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.26 | |||||
| Operating Margin % | -1459.52 | |||||
| Net Margin % | -1312.64 | |||||
| FCF Margin % | -1172.73 | |||||
| ROE % | -36.68 | |||||
| ROA % | -32.48 | |||||
| ROIC % | -118.52 | |||||
| ROC (Joel Greenblatt) % | -436.68 | |||||
| ROCE % | -38.15 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 61.27 | |||||
| PB Ratio | 2.04 | |||||
| Price-to-Tangible-Book | 2.04 | |||||
| EV-to-EBIT | -2.44 | |||||
| EV-to-Forward-EBIT | -0.81 | |||||
| EV-to-EBITDA | -2.48 | |||||
| EV-to-Revenue | 35.59 | |||||
| EV-to-Forward-Revenue | 17.01 | |||||
| EV-to-FCF | -3.03 | |||||
| Price-to-Net-Current-Asset-Value | 2.31 | |||||
| Price-to-Net-Cash | 2.52 | |||||
| Earnings Yield (Greenblatt) % | -40.98 | |||||
| FCF Yield % | -18.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AGIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Agios Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 26.823 | ||
| EPS (TTM) ($) | -6.34 | ||
| Beta | 0.43 | ||
| Volatility % | 52.16 | ||
| 14-Day RSI | 51.92 | ||
| 14-Day ATR ($) | 1.216102 | ||
| 20-Day SMA ($) | 29.2865 | ||
| 12-1 Month Momentum % | 36.46 | ||
| 52-Week Range ($) | 19.795 - 35.5 | ||
| Shares Outstanding (Mil) | 56.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Agios Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Agios Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Agios Pharmaceuticals Inc Frequently Asked Questions
What is Agios Pharmaceuticals Inc(AGIO)'s stock price today?
The current price of AGIO is $29.26. The 52 week high of AGIO is $35.50 and 52 week low is $19.80.
When is next earnings date of Agios Pharmaceuticals Inc(AGIO)?
The next earnings date of Agios Pharmaceuticals Inc(AGIO) is 2024-05-03 Est..
Does Agios Pharmaceuticals Inc(AGIO) pay dividends? If so, how much?
Agios Pharmaceuticals Inc(AGIO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers